← Mast Cell Activation Syndrome

Symptoms, Diagnosis, and Natural Support

Why mast cells over-fire — and how diet, flavonoids, and gut healing can calm an over-reactive immune system

Mast cell activation syndrome (MCAS) is a chronic, multi-system condition where mast cells — immune cells that normally guard against threats — fire off inflammatory chemicals at the wrong times and at the wrong intensity. The result is a confusing mix of flushing, hives, abdominal pain, brain fog, racing heart, food sensitivities, and fatigue that can shift week to week [1]. It's increasingly recognized as a hidden driver behind hard-to-explain symptoms, and many people with MCAS spend years bouncing between specialists before getting a name for what's happening. The good news: targeted diet changes, natural mast cell stabilizers, and gut support can substantially reduce flare-ups [3].

What Mast Cells Actually Do

Mast cells live in tissues exposed to the outside world — your skin, gut lining, airways, and around blood vessels — where they act as sentinels for the immune system. When triggered by infection, injury, allergens, or stress, they release a cocktail of more than 200 mediators including histamine, tryptase, prostaglandins, leukotrienes, heparin, and inflammatory cytokines [1]. In healthy people, this response is precise and protective.

In MCAS, mast cells become hyper-reactive: they degranulate too easily, in response to too many triggers, and don't switch off properly [2]. Unlike systemic mastocytosis (a related but rarer disease where mast cell numbers are increased), in MCAS the mast cell count is usually normal — the problem is behavioral, not numerical [1].

The Three Core Diagnostic Criteria

The current diagnostic framework, originally proposed by Akin, Valent, and Metcalfe in 2010 [2] and refined in the 2020 global "consensus-2" guidelines [1], rests on three pillars:

  1. Episodic, multi-system symptoms consistent with mast cell mediator release affecting at least two organ systems (skin, gut, cardiovascular, respiratory, neurologic)
  2. Objective evidence of mast cell mediator elevation during a flare — most commonly serum tryptase, but also urinary N-methylhistamine, prostaglandin D2 metabolites, or leukotriene E4
  3. Symptom improvement with mast cell-targeted therapy — H1/H2 antihistamines, mast cell stabilizers, or leukotriene blockers

The catch: mediator levels normalize between flares, so timing of testing matters enormously. Many people with real MCAS test "normal" because their labs were drawn during a quiet period [3].

Why Symptoms Are So Confusing

Because mast cells live everywhere and release dozens of mediators, MCAS symptoms span almost every body system. Common presentations include [3]:

  • Skin: flushing, urticaria (hives), itching, dermatographism (writing on the skin produces welts), angioedema
  • Gut: abdominal pain, nausea, bloating, alternating diarrhea and constipation, food sensitivities, reflux
  • Cardiovascular: racing heart, palpitations, low blood pressure, lightheadedness on standing (often overlapping with POTS)
  • Respiratory: congestion, wheezing, shortness of breath, throat tightness
  • Neurologic: brain fog, headaches, anxiety, sleep disturbance, sensory hyperreactivity
  • Systemic: fatigue, temperature dysregulation, food and chemical sensitivities, slow wound healing

Triggers are also unusually broad: heat, cold, stress, exercise, fragrance, alcohol, certain foods, hormonal shifts, infections, and even strong emotions can all set off a flare. This is why MCAS so often gets misdiagnosed as anxiety, IBS, chronic fatigue, fibromyalgia, or "just stress" [6].

The MCAS-POTS-hEDS Triad

A growing body of clinical observation suggests MCAS clusters with two other conditions: postural orthostatic tachycardia syndrome (POTS) and hypermobile Ehlers-Danlos syndrome (hEDS). Patients often have all three, and the combination is sometimes called "the triad" [3]. The shared thread appears to involve connective tissue fragility, autonomic nervous system dysregulation, and immune-mast cell hyperactivity reinforcing each other.

If you have MCAS-like symptoms plus orthostatic intolerance (lightheadedness on standing) and joint hypermobility, evaluation for the full triad is warranted.

Histamine Intolerance vs MCAS — Important Distinction

These conditions can look identical, but they're mechanistically different. In histamine intolerance, mast cells work normally, but the diamine oxidase (DAO) enzyme that breaks down dietary histamine is deficient — symptoms come from food. In MCAS, the mast cells themselves are dysfunctional and release histamine plus many other mediators, regardless of diet [3].

Some people have both. If a low-histamine diet helps but doesn't fully resolve symptoms, MCAS may be involved. See our Histamine Intolerance page for the dietary-side picture.

Natural Mast Cell Stabilizers

Several natural compounds have credible research showing they can stabilize mast cell membranes and reduce mediator release. These work as supportive therapy alongside, not instead of, medical evaluation.

Quercetin is the most-studied dietary flavonoid for mast cells. In a randomized double-blind trial, quercetin proved more effective than cromolyn (the prescription mast cell stabilizer) at blocking cytokine release from human mast cells, and reduced contact dermatitis and photosensitivity symptoms in humans [5]. Typical dosing in studies: 500–1000 mg twice daily of a high-bioavailability form. See our Quercetin page for more.

Luteolin is structurally similar to quercetin and shows complementary effects, including better blood-brain barrier penetration — potentially useful for the neurologic symptoms of MCAS [4]. Often combined with quercetin.

Vitamin C supports DAO activity, has its own antihistamine effect, and is depleted during mast cell flares. Doses of 500–2000 mg daily are commonly used [3].

Vitamin D deficiency is associated with mast cell hyperreactivity; correcting low levels is a sensible first step.

Other supportive options with mechanistic but more limited human MCAS data: omega-3s (anti-inflammatory), N-acetylcysteine (helps clear oxidative stress from mast cell flares), and curcumin (broad anti-inflammatory and mast cell signaling effects).

Diet: Low-Histamine Plus Low-Trigger

Most people with MCAS feel meaningfully better on a low-histamine diet, even though histamine is only one of many mediators involved [3]. Foods to reduce or eliminate during a flare:

  • Aged, fermented, smoked, or cured foods (cheese, sauerkraut, salami, kombucha)
  • Leftover meat and fish (histamine builds up after cooking)
  • Alcohol (especially red wine and beer — high histamine and blocks DAO)
  • Tomatoes, citrus, strawberries, avocado, spinach, eggplant, nuts (histamine liberators)
  • Food additives: artificial colors, sulfites, benzoates, MSG

In addition to histamine, individuals often have personal triggers — common ones include high-salicylate foods, high-oxalate foods, lectins, or specific FODMAPs. A symptom-tracking journal during a 4–6 week elimination phase is the most reliable way to identify yours.

Gut Health: The Often-Missed Foundation

The gut wall houses the largest concentration of mast cells in the body, and gut dysfunction and MCAS reinforce each other. Leaky gut allows undigested food particles and bacterial fragments to reach mast cells, triggering them. Activated mast cells, in turn, increase gut permeability and disrupt motility [3].

Repairing gut integrity is therefore central to long-term MCAS management. See our Leaky Gut page for repair strategies — particular attention to L-glutamine, zinc carnosine, slippery elm, and removing gut irritants tends to help. Treating coexisting SIBO is often essential, since bacterial overgrowth produces histamine directly inside the gut.

When to Seek Medical Evaluation

Self-management gets many people 60–70% better, but several situations warrant a specialist (typically an allergist/immunologist or hematologist familiar with mast cell disease):

  • Anaphylaxis or near-anaphylaxis episodes
  • Symptoms severe enough to interfere with work or daily life
  • Failure to improve with diet and basic supplement support
  • Suspicion of systemic mastocytosis (very high tryptase, bone pain, organomegaly)

Prescription options include H1 and H2 antihistamines (used together, often at doses higher than allergy treatment), cromolyn sodium, leukotriene receptor antagonists like montelukast, and in selected cases low-dose ketotifen or omalizumab [3].

Evidence Review

Establishing MCAS as a Distinct Entity

The conceptual foundation for MCAS was laid by Akin, Valent, and Metcalfe in their 2010 Journal of Allergy and Clinical Immunology paper (PMID 21035176), which formally proposed diagnostic criteria for patients who had clear evidence of mast cell mediator release without meeting criteria for systemic mastocytosis [2]. They defined MCAS as a clinical syndrome requiring three elements: characteristic episodic symptoms across multiple organ systems, evidence of mast cell mediator elevation during attacks, and response to mast cell-targeted therapy. These criteria remain the backbone of "consensus-1" diagnosis used by mainstream allergy/immunology.

A parallel framework, sometimes called "consensus-2," was developed by Molderings and colleagues to address what they argue is a much broader population — patients with chronic multi-system mast cell symptoms who don't always meet the strict mediator-elevation thresholds of consensus-1. The 2020 global consensus-2 paper by Afrin and 39 co-authors (PMID 32324159) is the most comprehensive articulation of this framework, drawing on over 10,000 cumulative patient cases across the contributing clinicians [1]. The two frameworks differ in stringency but agree on core mechanism: aberrant chronic mast cell activation producing multi-system inflammatory symptoms.

Clinical Recognition and Misdiagnosis

Afrin et al. (2017, PMID 27012973, Annals of Medicine) reviewed the clinical phenotype of MCAS in detail, documenting that symptoms typically begin in childhood or adolescence and worsen progressively, that average diagnostic delay is 7–10 years, and that patients are commonly misdiagnosed with chronic fatigue syndrome, fibromyalgia, IBS, anxiety, somatization, or "functional" disorders before MCAS is identified [6]. The paper notes that mediator testing is highly state-dependent — drawn during a flare, tryptase elevations are often present; drawn between flares, even severely affected patients can show "normal" labs. This temporal sensitivity is a major contributor to under-recognition.

Gastrointestinal Connection

Weinstock, Pace, Rezaie, Afrin, and Molderings (2021, PMID 32328892, Digestive Diseases and Sciences) reviewed the gastrointestinal manifestations of MCAS in detail [3]. They documented that GI symptoms occur in over 80% of MCAS patients and frequently lead to misdiagnosis as IBS, IBD, or functional dyspepsia. Mechanisms reviewed include direct mast cell-driven smooth muscle dysmotility, increased intestinal permeability ("leaky gut") secondary to mast cell mediator release, visceral hypersensitivity from mast cell-nerve signaling, and reciprocal exacerbation between SIBO and mast cell hyperreactivity. They proposed that gastroenterologists should specifically consider MCAS in patients with refractory IBS-like symptoms accompanied by extra-intestinal features (flushing, dermatographism, palpitations).

Mast Cell Stabilization by Flavonoids

Weng et al. (2012, PMID 22470478, PLoS One) conducted a translational study comparing the prescription mast cell stabilizer cromolyn to the natural flavonoid quercetin in human mast cell cultures [5]. Quercetin demonstrated superior inhibition of TNF-α, IL-6, and IL-8 release from human cord blood-derived mast cells. The study then extended into a small human trial: in patients with contact dermatitis and photosensitivity, oral quercetin reduced visual analog scale symptom scores significantly versus pre-treatment baseline. The authors concluded that quercetin could be considered a viable alternative or adjunct to cromolyn for some mast cell-mediated conditions, with the practical advantage of being available without prescription. Limitation: the human trial was open-label and small.

Shaik et al. (2018, PMID 30799996, Central European Journal of Immunology) reviewed the mechanistic literature on polyphenol-mast cell interactions, with particular attention to quercetin and luteolin [4]. Both flavonoids inhibit mast cell degranulation through interference with PI3K, MAPK, and ERK signaling pathways downstream of FcεRI receptor activation. Quercetin specifically suppresses histidine decarboxylase mRNA, reducing the cell's capacity to synthesize new histamine. Luteolin uniquely inhibits production of IL-6, IL-8, and VEGF from mast cells and TNF-triggered keratinocytes. The authors highlighted luteolin's blood-brain barrier penetration as making it potentially useful for the neuro-cognitive symptoms of mast cell hyperactivity, an area where pharmaceutical mast cell stabilizers are less effective.

Post-Viral and Long-COVID Connection

Afrin, Weinstock, and Molderings (2020, PMID 32920235, International Journal of Infectious Diseases) proposed that the cytokine-storm phenomenon of severe COVID-19 and the persistent multi-system symptoms of long COVID may be substantially mediated by mast cell hyperactivation [7]. The hypothesis is grounded in the substantial overlap between long-COVID symptom clusters and pre-existing MCAS phenotypes, the well-established role of mast cells in viral inflammation, and clinical reports of long-COVID patients responding to mast cell-targeted therapy. While the paper is hypothesis-generating rather than definitive, it spurred a wave of clinical and research attention to mast cells in post-viral syndromes, and many post-viral chronic illness clinics now routinely screen for and treat empirically for MCAS.

Strength and Limits of the Evidence

The strongest evidence in MCAS is mechanistic and observational: clear demonstration that mast cell mediators cause the symptom profile, and consistent clinical response to mast cell-targeted therapy across thousands of documented cases [1][6]. Where the evidence remains weaker is in randomized controlled trial data — large RCTs of MCAS-specific interventions are scarce, partly because of diagnostic heterogeneity and partly because the syndrome was only formally defined within the past 15 years. Most clinical recommendations, including for natural stabilizers like quercetin and luteolin, are extrapolations from cell culture studies, animal models, and small open-label human trials. This is a field where evidence is evolving rapidly and where patient experience and clinical observation continue to lead RCT confirmation by years.

References

  1. Diagnosis of mast cell activation syndrome: a global consensus-2Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, Cuni JR, Davey WP, Dempsey TT, Dorff SR, Dubravec MS, Guggenheim AG, Hindman KJ, Hoffman B, Kaufman DL, Kratzer SJ, Lee TM, Marantz MS, Maxwell AJ, McCann KK, McKee DL, Menk Otto L, Pace LA, Perkins DD, Radano L, Raleigh MS, Rapaport SA, Reinhold EJ, Renneker ML, Robinson WA, Roland AM, Rosenbloom ES, Rowe PC, Ruhoy IS, Saperstein DS, Schlosser DA, Schofield JR, Settle JE, Weinstock LB, Wengenroth M, Westaway M, Xi SC, Molderings GJ. Diagnosis (Berlin), 2020. PubMed 32324159 →
  2. Mast cell activation syndrome: Proposed diagnostic criteriaAkin C, Valent P, Metcalfe DD. Journal of Allergy and Clinical Immunology, 2010. PubMed 21035176 →
  3. Mast Cell Activation Syndrome: A Primer for the GastroenterologistWeinstock LB, Pace LA, Rezaie A, Afrin LB, Molderings GJ. Digestive Diseases and Sciences, 2021. PubMed 32328892 →
  4. Impact of polyphenols on mast cells with special emphasis on the effect of quercetin and luteolinShaik Y, Caraffa A, Ronconi G, Lessiani G, Conti P. Central European Journal of Immunology, 2018. PubMed 30799996 →
  5. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humansWeng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC. PLoS One, 2012. PubMed 22470478 →
  6. Often seen, rarely recognized: Mast cell activation disease — A guide to diagnosis and therapeutic optionsAfrin LB, Self S, Menk J, Lazarchick J. Annals of Medicine, 2017. PubMed 27012973 →
  7. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndromeAfrin LB, Weinstock LB, Molderings GJ. International Journal of Infectious Diseases, 2020. PubMed 32920235 →

Weekly Research Digest

Get new topics and updated research delivered to your inbox.